Table 2 Baseline characteristics of included studies
Study ID | Doses | Number of patients | Age mean (SD) | Males no. (%) | BMI mean (SD) | Lipid metabolism mean (SD) | Lipid Therapy no. (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total triglycerides | Total cholesterol | LDL-C | HDL-C | APOC-III | Statins | Fibrates | Ezetimibe | PCSK-9 Inhibitors | ||||||
Ballantyne et al. 2024 [42] | plozasiran 10Â mg Q12 W | 67 | 60.2 (11.7) | 36 (54) | 30.5 (5.7) | 253.2 (81.4) | NA | 105.1 (37.0) | 42.2 (11.1) | 15.5 (5.5) | 61 (91) | 10 (15) | NA | 3 (4) |
plozasiran 25Â mg Q12 W | 67 | 61.3 (11.3) | 37 (55) | 32.4 (6.7) | 234.1 (72.7) | NA | 101.6 (43.4) | 44.7 (13.6) | 15.6 (5.5) | 61 (91) | 6 (9) | NA | 3 (4) | |
plozasiran 50Â mg Q12 W | 66 | 62.6 (10.5) | 37 (56) | 32.6 (6.5) | 250.3 (81.3) | NA | 103.0 (39.7) | 42.7 (11.7) | 15.0 (5.7) | 60 (91) | 6 (9) | NA | 0 | |
plozasiran 50Â mg Q24 W | 66 | 61.3 (11.8) | 43 (65) | 32.0 (5.6) | 248.0 (80.6) | NA | 105.6 (31.8) | 40.8 (12.6) | 15.0 (5.5) | 57 (86) | 9 (14) | NA | 1 (2) | |
Placebo | 87 | 58.9 (9.7) | 46 (53) | 31.2 (5.4) | 237.2 (76.2) | NA | 101.6 (38.7) | 42.1 (11.1) | 14.6 (4.7) | 84 (97) | 15 (17) | NA | 1 (1) | |
Bergmark et al. 2024 [43] | Olezarsen 50Â mg Q4W | 58 | 62.66 (12.92) | 34(59) | 33.66 (6.61) | 248 (113.27) | 130.7 (40) | 83.1 (35.35) | NA | 15.53 (5.54) | 49(84) | 5 (9) | 5 (9) | 3 (5) |
Olezarsen 80Â mg Q4W | 57 | 61 (11.40) | 40(70) | 32.2 (6.84) | 259.5 (135.37) | 128.8 (30.7) | 81.5 (30.42) | NA | 14.26 (4.86) | 46 (81) | 9 (16) | 2 (4) | 1 (2) | |
Placebo | 39 | 64 (10.00) | 15(38) | 33.6 (5.54) | 251.1 (50.02) | 135.3 (39.6) | 82.66 (32.71) | NA | 15.9(4.23) | 32 (82) | 11 (28) | 3 (8) | 1 (3) | |
Stroes et al. 2024 [40] | Olezarsen 50Â mg Q4W | 21 | 43.2 (12.1) | 6(29) | 22.4 (3.5) | 2684 (1235) | 323.4 (100.5) | 17.6 (8.5) | 15.7 (4.0) | 27.7 (10.5) | 4 (19) | 8 (38) | NA | NA |
Olezarsen 80Â mg Q4W | 22 | 47.7 (13.3) | 11 (50) | 25.1 (6.0) | 2613 (1499) | 277.4 (99.3) | 22.8 (14.1) | 14.5 (4.5) | 27.5 (11.6) | 5 (23) | 11 (50) | NA | NA | |
Placebo | 23 | 44.0 (14.7) | 11 (48) | 24.2 (4.1) | 2596 (1256) | 286.0 (113.9) | 16.7 (8.4) | 14.7 (3.8) | 27.7 (11.7) | 7 (30) | 11 (48) | NA | NA | |
Tardif et al. 2022 [41] | Olezarsen 50Â mg Q4W | 22 | 62.9 (7.40) | 15 (68.2) | 32.8 (4.14) | 268.4 (85.1) | 166.8 (35.3) | 76.8 (20.8) | 36.8 ( 10.5) | 15.7 (3.3) | 19 (86.4) | 10 (45.5) | 3 (13.6) | 2 (9.1) |
Placebo | 24 | 64.6 (7.93) | 20 (83.3) | 32.1 (4.18) | 293.8 (86.7) | 144.8 (26.0) | 60.2 (27.2) | 34.6 ( 8.6) | 16.6 (4.5) | 23 (95.8) | 8 (33.3) | 4 (16.7) | 1 (4.2) | |
Gaudet et al. 2024 [21] | plozasiran 10Â mg Q12 W | 54 | 53 (10) | 46 (85) | 33 (5) | 890 (577) | 209 (74) | 75 (44) | 28 (9) | 33 (15) | 35 (65) | 26 (48) | NA | 1 (2) |
plozasiran 25Â mg Q12 W | 55 | 56 (11) | 43 (78) | 32 (5) | 942 (756) | 206 (91) | 74 (40) | 30 (11) | 34 (17) | 39 (71) | 24 (44) | NA | 2 (4) | |
plozasiran 50Â mg Q12 W | 57 | 54 (11) | 41 (72) | 32 (5) | 908 (653) | 196 (88) | 72 (42) | 31 (13) | 32 (16) | 39 (70) | 28 (50) | NA | 1 (2) | |
Placebo | 60 | 56 (11) | 46 (77) | 31 (4) | 851 (507) | 185 (79) | 69 (39) | 30 (12) | 31 (16) | 41 (67) | 31 (51) | NA | 3 (5) | |
Gaudet et al. 2023 [38] | plozasiran 10Â mg Q4 W | 8 | 53 | 7 (87.5) | 31.9 (4.5) | 664 (325.01) | 238.3 (105.3) | 88.3 (26.6) | 26.8 (8.9) | 28.4 (10.3) | 6 (75.0) | 1 (12.5) | NA | NA |
plozasiran 25Â mg Q4 W | 8 | 55.5 | 6 (75.0) | 31.5 (3.4) | 1252.75 (1007.04) | 327.4 (181.1) | 76.8 (47.3) | 28.8 (8.1) | 41.5 (21.6) | 5 (62.5) | 3 (37.5) | NA | NA | |
plozasiran 50Â mg Q4 W | 8 | 54.5 | 4 (50.0) | 30.5 (7.0) | 723.75 (395.87) | 238.8 (82.6) | 82.8 (38.1) | 30.0 (7.0) | 24.5 (12.6) | 2 (25.0) | 4 (50.0.) | NA | NA | |
plozasiran 100Â mg Q4 W | 8 | 57.5 | 6 (75.0) | 32.2 (3.6) | 688.25 (351.53) | 237.0 (59.1) | 95.1 (55.7) | 33.3 (13.9) | 30.2 (14.5) | 2 (25.0) | 2 (25.0) | NA | NA | |
Placebo | 8 | 46.5 | 6 (75.0) | 30.7 (5.0) | 680.5 (467.33) | 195.0 (48.0) | 79.8 (44.5) | 27.5 (7.8) | 22.8 (7.4) | 3 (37.5) | 3 (37.5) | NA | NA | |
Gaudet et al. 2014 [16] | volanesorsen 100Â mg Q1W | 13 | 52.2 (9.7) | 8 (61.54) | 29.4 (4.1) | 573.2 (248.5) | 235.0 (50.3) | 95.6 (33.3) | 31.5 (4.7) | 22.4 (7.7) | 6 (46.2) | NA | NA | NA |
volanesorsen 200Â mg Q1W | 15 | 49.7 (12.8) | 14 (93.33) | 30.8 (3.0) | 662.0 (299.0) | 240.5 (62.7) | 79.5 (25.1) | 31.9 (4.0) | 23.1 (5.3) | 4 (26.7) | NA | NA | NA | |
volanesorsen 300Â mg Q1W | 13 | 52.8 (10.4) | 8 (61.54) | 30.9 (3.6) | 565.6 (213.7) | 208.9 (58.7) | 70.9 (31.0) | 33.2 (8.9) | 22.6 (6.3) | 5 (38.5) | NA | NA | NA | |
Placebo | 16 | 48.6 (11.9) | 13 (81.25) | 31.1 (3.0) | 522.7 (369.7) | 241.1 (81.2) | 105.1 (56.3) | 33.0 (7.5) | 22.2 (7.7) | 4 (25.0) | NA | NA | NA | |
Gouni et al. 2021 [39] | volanesorsen 300Â mg Q1W | 25 | 50.5 (9) | 20 (80) | 30.7 (3.8) | 1046 (560) | 236 (38) | 64 (29) | 25 (7) | 33 (10) | NA | NA | NA | NA |
volanesorsen 300Â mg Q2W | 50 | 50 (11.75) | 36 (72) | 32.1 (6.4) | 1251 (838) | 267 (110) | 64 (29) | 25 (7) | 36 (17) | NA | NA | NA | NA | |
Placebo | 38 | 54 (12.25) | 30 (79) | 30.3 (4.4) | 1414 (1253) | 279 (152) | 56 (28) | 24 (8) | 34 (15) | NA | NA | NA | NA | |
Oral et al. 2022 [31] | volanesorsen 300Â mg Q1W | 21 | 46 (10) | 14 (73.7) | 30.9 (6.4) | 1432.25 (952.25) | 246 (127) | 65 (32) | 30 (11) | 34.6 (19.3) | NA | NA | NA | NA |
Placebo | 19 | 48 (12) | 5 (26.3) | 30.6 (5.3) | 1838.75 (1223) | 254 (120) | 74 (32) | 24 (8) | 37.1 (20.4) | NA | NA | NA | NA | |
Witztum et al. 2019 [29] | volanesorsen 300Â mg Q1W | 33 | 47 (13.25) | 16 (48.48) | 25.9 (6.5) | 2367 (1315) | NA | 28 (19) | 17 (4) | 31.42 (15.29) | NA | NA | NA | NA |
Placebo | 33 | 46 (12) | 14 (42.42) | 24.1 (4.7) | 2152 (1153) | NA | 28 (13) | 17 (4) | 28.94 (13.08) | NA | NA | NA | NA | |